VNRX
VolitionRX Ltd
VNRX
VolitionRX Ltd
Reduces Equity Overhang HENDERSON, Nev., Sept. 14, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the full pre-paymen
Targets $36 Billion TAM in Early Cancer Detection and MRD. HENDERSON, Nev.
112% H1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, Newly Announced Collaboration and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders HENDERSON, Nev.,
Published in Critical Care Medicine , findings confirm high-predictive accuracy for severe sepsis outcomes, driving commercial momentum across Volition's $2.8 billion addressable market. HENDERSON, Ne
Removes Centralized Lab Dependency for $3.8 Billion Global Addressable Market for NETosis Testing HENDERSON, Nev., Aug. 12, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"),
Targets $36 Billion TAM in Early Cancer Detection and MRD. Company in active discussions with global diagnostic leaders to accelerate commercialization.
Consistent international data positions Nu.Q® H3.1 as a potential "game changer" in sepsis management within a $3.8 billion addressable market HENDERSON, Nev., July 30, 2026 /PRNewswire/ -- VolitionRx
HENDERSON, Nev., July 7, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the release of a new clinical study demonstra